Table 1.
Study population
| IVIG-resistant KD (KAWAKINRA study cohort [17]) n = 16 | sJIA-MAS (n = 9) |
MIS-C (n = 4) |
Pediatric HC (n = 4) |
|
|---|---|---|---|---|
| Sex, no. (%) | ||||
| Female | 2 (13) | 5 (55) | 1 (25) | 2 (50) |
| Male | 14 (87) | 4 (45) | 3 (75) | 2 (50) |
| Age (years), median (range) | 2.58 (0.25–6.9) | 17.8 (8–19) | 10 (8–15) | 11 (7–15) |
| Clinical laboratory parameters, median (range) | ||||
| CRP, mg/dL | 13.5 (2.5–40.3)§ | 11.8 (5–25.7) | 26.3 (11.8–32.7) | n.d |
| Ferritin, µg/L | n.d | 3385 (1476–25,977) | 2749 (1039–4195) | n.d |
| Hemoglobin, d/dL | 9.2 (7.6–11.9)§ | 11.1 (9.6–11.6) | 10.5 (7.8–11.9) | n.d |
| Leukocytes/mm3 | 15,335 (6999–30,550)§ | 7080 (2700–34,300) | 24,590 (17,750–30,860) | n.d |
| Neutrophils/mm3 | 10,375 (3600–28,530)§ | 4270 (400–8800) | 9863 (6380–14,470) | n.d |
| Thrombocytes × 109/L | 496 (194–879)§ | 158 (13–446) | 117.9 (102–776) | n.d |
| Medication | ||||
| Naive | 0/16 | 1/9 | 0/4 | 4/4 |
| IVIG | 16/16 | 0/9 | 4/4 | 0/4 |
| Anakinra | 16/16 | 4/9 | 0/4 | 0/4 |
| Steroids | 3/16 | 8/9 | 4/4 | 0/4 |
| Tocilizumab | 0/16 | 2/9 | 0/4 | 0/4 |
| CSA | 0/16 | 2/9 | 0/4 | 0/4 |
CRP C-reactive protein; HC healthy control; IVIG intravenous immunoglobulin; KD Kawasaki disease; MIS-C multi-system inflammatory syndrome in children
§Clinical laboratory values at screening visit